566913-35-7

Upstream product

• 566913-34-6 4-methyl-6,8-di-iso-propylcoumarin 

Downstream Products

• 566913-41-5 (Z)-(3,5-di-iso-propyl-2-butoxyphenyl)but-2-en-1-ol 
• 566913-62-0 (Z)-[3,5-di-iso-propyl-2-(2,2,2-trifluoroethoxyphenyl)]but-2-en-1-ol 
• 566913-38-0 (Z)-3-[3,5-di-iso-propyl-2-(2-fluoroethoxy)phenyl]but-2-en-1-ol 
• 566913-36-8 (Z)-3-(3,5-di-iso-propyl-2-methoxyphenyl)but-2-en-1-ol 
• 566913-83-5 (Z)-3-[3,5-di-iso-propyl-2-(2,2,2-trifluoroethoxy)phenyl]but-2-en-1-al 
• 460048-42-4 (Z)-2-(3,5-di-iso-propyl-2-butoxyphenyl)but-2-en-1-al 
• 566913-47-1 (Z)-3-[3,5-di-iso-propyl-2-(2,2-difluoroethoxy)phenyl]but-2-en-1-al 
• 566913-46-0 (Z)-3-[3,5-di-iso-propyl-2-(2-fluoroethoxy)phenyl]but-2-en-1-al 
• 566913-48-2 (Z)-3-(3,5-di-iso-propyl-2-propoxyphenyl)but-2-en-1-al 
• 566913-45-9 (Z)-3-(3,5-di-iso-propyl-2-ethoxyphenyl)but-2-en-1-al 

Relevant academic research and scientific papers

3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity

Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.

Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes

Previous data have shown that RXR-selective agonists (e.g., 3 and 4) are insulin sensitizers in rodent models of non-insulin-dependent diabetes mellitus (NIDDM). Unfortunately, they also produce dramatic increases in triglycerides and profound suppression